12 minute read
Apr. 3, 2024
MK-0616: "I Was Told... an Oral PCSK9 Inhibitor is Impossible"
MK-0616
oral macrocyclic peptide inhibitor of PCSK9 Ph. III for hypercholesterolemia planned 2H 2023 from mRNA display + SBDD J. Am. Coll. Cardiol., April 25, 2023 Merck, Rahway, NJ
Loading...
